Evidence map›Paper›PMID 35625961›Full record

ArticleCancers2022

Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown.

Lisa Kostner, Sara Elisa Cerminara, Gustavo Santo Pedro Pamplona, Julia-Tatjana Maul, Reinhard Dummer, Egle Ramelyte, Johanna Mangana, Nikolaus Benjamin Wagner, Antonio Cozzio, Saskia Kreiter and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

Lisa KostnerDepartment of Dermatology, University Hospital of Basel, 4031 Basel, Switzerland.
Sara Elisa CerminaraDepartment of Dermatology, University Hospital of Basel, 4031 Basel, Switzerland.
Gustavo Santo Pedro PamplonaDepartment of Ophthalmology, University of Lausanne, 1004 Lausanne, Switzerland.ORCID 0000-0002-0278-203X
Julia-Tatjana MaulDepartment of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland.
Reinhard DummerDepartment of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0002-2279-6906
Egle RamelyteDepartment of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland.
Johanna ManganaDepartment of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland.
Nikolaus Benjamin WagnerDepartment of Dermatology, Cantonal Hospital of St. Gallen, 9000 St. Gallen, Switzerland.ORCID 0000-0003-4708-2886
Antonio CozzioDepartment of Dermatology, Cantonal Hospital of St. Gallen, 9000 St. Gallen, Switzerland.
Saskia KreiterDepartment of Dermatology, Cantonal Hospital of St. Gallen, 9000 St. Gallen, Switzerland.
Angelika KoglerDepartment of Dermatology, Cantonal Hospital of St. Gallen, 9000 St. Gallen, Switzerland.
Markus StreitDepartment of Dermatology, Cantonal Hospital of Aarau, 5001 Aarau, Switzerland.
Anja WysockiDepartment of Dermatology, Cantonal Hospital of Lucerne, 6000 Lucerne, Switzerland.
Alfred ZippeliusDepartment of Theragnostics, Division of Oncology, University Hospital Basel, 4031 Basel, Switzerland.
Heinz LäubliDepartment of Theragnostics, Division of Oncology, University Hospital Basel, 4031 Basel, Switzerland.
Alexander Andreas NavariniDepartment of Dermatology, University Hospital of Basel, 4031 Basel, Switzerland.
Lara Valeska MaulDepartment of Dermatology, University Hospital of Basel, 4031 Basel, Switzerland.ORCID 0000-0001-9202-0073
University Hospital of Basel · CHUniversity Hospital of Zurich · CHUniversity of St.Gallen · CHUniversity of Basel · CHETH Zurich · CHKantonsspital Aarau · CHUniversity of Lucerne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At the early stages of the COVID-19 outbreak in 2020, Switzerland was among the countries with the highest number of SARS-CoV2-infections per capita in the world. Lockdowns had a remarkable impact on primary care access and resulted in postponed cancer screenings. The aim of this study was to investigate the effects of the COVID-19 lockdown on the diagnosis of melanomas and stage of melanomas at diagnosis. In this retrospective, exploratory cohort study, 1240 patients with a new diagnosis of melanoma were analyzed at five tertiary care hospitals in German-speaking Switzerland over a period of two years and three months. We compared the pre-lockdown (01/FEB/19-15/MAR/20, n = 655) with the lockdown (16/MAR/20-22/JUN/20, n = 148) and post-lockdown period (23/JUN/20-30/APR/21, n = 437) by evaluating patients' demographics and prognostic features using Breslow thickness, ulceration, subtype, and stages. We observed a short-term, two-week rise in melanoma diagnoses after the major lift of social lockdown restrictions. The difference of mean Breslow thicknesses was significantly greater in older females during the lockdown compared to the pre-lockdown (1.9 ± 1.3 mm,

Indexed as

ageBreslow thicknessCOVID-19diagnostic delaygenderlockdownmelanoma

Identifiers

PMID35625961
PMCPMC9139530
OpenAlexW4280626761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.